Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer: A consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians.
The aim of this article is to inform about cancer treatment-induced bone loss, to identify patients at risk and those that can benefit from bone targeted treatment as well as highlight the importance of the multidisciplinary approach in the bone health in cancer care. Patients with breast cancer treated or intended to be treated with aromatase inhibitors belong to a high-risk group because their fracture risk increases up to 30% due to a significant decrease in bone mineral density within 6-12 months after the start of hormonal treatment. To evaluate bone status and predict risk for fractures, lateral thoracic and lumbar spine X-ray imaging, bone mineral density measurement by dual energy X-ray absorptiometry at the lumbar spine L1-L4 vertebrae and/or hip and fracture risk factors assessment are mandatory tests prior to hormonal treatment. Morbidity and mortality associated with bone loss can be prevented with appropriate screening, lifestyle interventions, and therapy. Algorithm for the management of bone health in breast cancer patients was established in Lithuania to screen patients with increased risk for bone loss and to provide adequate specific osteoporosis treatment.
Correspondence to E. Juozaitytė Institute of Oncology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania. Electronic address: email@example.com
Received 25 October 2013, accepted 15 September 2014, available online 1 October 2014.